NASDAQ:ORIC

ORIC Pharmaceuticals (ORIC) Stock Forecast, Price & News

$5.34

+0.30 (+5.95%)

(As of 02:32 PM ET)

Compare

Today's Range: $4.99
▼
$5.41
50-Day Range: $4.73
▼
$6.15
52-Week Range: $2.36
▼
$6.85

Volume: 114,335 shs
Average Volume: 206,946 shs
Market Capitalization: $240.78 million

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: $13.20

ORIC Pharmaceuticals MarketRank™ Forecast

Analyst Rating: Buy
3.00 Rating Score
Upside/Downside: 147.2% Upside
$13.20 Price Target
Short Interest: Bearish
13.67% of Float Sold Short
Dividend Strength: N/A
Sustainability: -0.58
Upright™ Environmental Score
News Sentiment: N/A
Insider Trading: N/A
Proj. Earnings Growth: Growing
From ($2.20) to ($2.02) Per Share

Overall MarketRank^™

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.33 out of 5 stars

Medical Sector

421st out of 1,980 stocks

Pharmaceutical Preparations Industry

181st out of 978 stocks

4.5

Analyst's Opinion

Consensus Rating
ORIC Pharmaceuticals has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 5 buy ratings, no hold ratings, and no sell ratings.
Price Target Upside/Downside
According to analysts' consensus price target of $13.20, ORIC Pharmaceuticals has a forecasted upside of 147.2% from its current price of $5.34.
Amount of Analyst Coverage
ORIC Pharmaceuticals has been the subject of 5 research reports in the past 90 days, demonstrating strong analyst interest in this stock.

0.0

Short Interest

Percentage of Shares Shorted
13.67% of the float of ORIC Pharmaceuticals has been sold short.
Short Interest Ratio / Days to Cover
ORIC Pharmaceuticals has a short interest ratio ("days to cover") of 27.5, which indicates bearish sentiment.
Change versus previous month
Short interest in ORIC Pharmaceuticals has recently increased by 0.94%, indicating that investor sentiment is decreasing.

0.0

Dividend Strength

Dividend Yield
ORIC Pharmaceuticals does not currently pay a dividend.
Dividend Growth
ORIC Pharmaceuticals does not have a long track record of dividend growth.

4.8

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score
ORIC Pharmaceuticals has received a 76.88% net impact score from Upright. The largest positive contribution comes from its "Physical diseases" impact, which is driven by its "Preclinical research services for physical health" and "Clinical research services for cancer" products. See details.
Environmental Sustainability
The Environmental Impact score for ORIC Pharmaceuticals is -0.58.

2.1

News and Social Media Coverage

News Sentiment
ORIC Pharmaceuticals has a news sentiment score of 0.84. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.63 average news sentiment score of Medical companies.
News Coverage This Week
MarketBeat has tracked 1 news article for ORIC Pharmaceuticals this week, compared to 1 article on an average week.
Search Interest
Only 1 people have searched for ORIC on MarketBeat in the last 30 days. This is a decrease of -90% compared to the previous 30 days.
MarketBeat Follows
Only 1 people have added ORIC Pharmaceuticals to their MarketBeat watchlist in the last 30 days. This is a decrease of -67% compared to the previous 30 days.

1.7

Company Ownership

Insider Buying vs. Insider Selling
In the past three months, ORIC Pharmaceuticals insiders have not sold or bought any company stock.
Percentage Held by Insiders
Only 5.34% of the stock of ORIC Pharmaceuticals is held by insiders.
Percentage Held by Institutions
82.65% of the stock of ORIC Pharmaceuticals is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

0.6

Earnings and Valuation

Earnings Growth
Earnings for ORIC Pharmaceuticals are expected to grow in the coming year, from ($2.20) to ($2.02) per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of ORIC Pharmaceuticals is -2.44, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Ratio vs. Sector
The P/E ratio of ORIC Pharmaceuticals is -2.44, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Book Value per Share Ratio
ORIC Pharmaceuticals has a P/B Ratio of 1.19. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

See Top Rated MarketRank™ Stocks Here

About ORIC Pharmaceuticals (NASDAQ:ORIC) Stock

ORIC Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, discovers and develops therapies for treatment of cancers in the United States. Its clinical stage product candidates include ORIC-533, an orally bioavailable small molecule inhibitor of CD73 being developed for resistance to chemotherapy- and immunotherapy-based treatment regimens; ORIC-944, an allosteric inhibitor of the polycomb repressive complex 2 for prostate cancer; and ORIC-114, a brain penetrant orally bioavailable irreversible inhibitor designed to selectively target epidermal growth factor receptor and human epidermal growth factor receptor 2 with high potency towards exon 20 insertion mutations. The company is also developing multiple discovery stage precision medicines targeting other cancer resistance mechanisms. It has a license and collaboration agreement with Voronoi Inc.; and a license agreement with Mirati Therapeutics, Inc. The company was incorporated in 2014 and is headquartered in South San Francisco, California.

Receive ORIC Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for ORIC Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

ORIC Stock News Headlines

May 31, 2023 | finance.yahoo.com

ORIC Pharmaceuticals to Participate in the Jefferies Healthcare Conference

May 14, 2023 | americanbankingnews.com

Q2 2023 Earnings Estimate for ORIC Pharmaceuticals, Inc. (NASDAQ:ORIC) Issued By HC Wainwright

June 1, 2023 | Edge On The Street (Ad)

AI is Unstoppable. Now Is The Time!

AI, or Artificial Intelligence, is all the rage right now. AI technologies are empowering users in every industry to increase sales, efficiency, and productivity. It's truly a case of adapt or fail.

May 12, 2023 | msn.com

HC Wainwright & Co. Maintains ORIC Pharmaceuticals (ORIC) Buy Recommendation

May 11, 2023 | americanbankingnews.com

ORIC Pharmaceuticals (NASDAQ:ORIC) Price Target Cut to $14.00 by Analysts at HC Wainwright

May 8, 2023 | msn.com

ORIC Pharmaceuticals GAAP EPS of -$0.53

May 8, 2023 | finance.yahoo.com

ORIC Pharmaceuticals Reports First Quarter 2023 Financial Results and Operational Updates

May 5, 2023 | finance.yahoo.com

ORIC Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

June 1, 2023 | Edge On The Street (Ad)

Graphite Shortage Could Derail the $7 Trillion EV Transition

Graphite (not lithium) is expected to see the largest increase in demand of all battery metals over the next decade. But projections warn of an 8 million ton shortfall of graphite by 2040. That's why 97 more graphite mines are needed just to keep up with battery production for the $7 trillion transition to electric vehicles.

April 25, 2023 | finance.yahoo.com

ORIC Pharmaceuticals to Participate in the H.C. Wainwright BioConnect Investor Conference

April 18, 2023 | finance.yahoo.com

ORIC Pharmaceuticals Presents Promising Preclinical Data on Two Programs at the 2023 American Association for Cancer Research (AACR) Annual Meeting

April 6, 2023 | msn.com

Citigroup Maintains ORIC Pharmaceuticals (ORIC) Buy Recommendation

April 5, 2023 | americanbankingnews.com

ORIC Pharmaceuticals (NASDAQ:ORIC) PT Lowered to $8.00 at Citigroup

March 31, 2023 | finance.yahoo.com

One ORIC Pharmaceuticals, Inc. (NASDAQ:ORIC) insider upped their stake by 128% in the previous year

March 29, 2023 | finance.yahoo.com

‘Charts Point to Higher Highs,’ Says Oppenheimer. Here Are 2 Stocks With Over 100% Upside Potential

March 26, 2023 | americanbankingnews.com

ORIC Pharmaceuticals (NASDAQ:ORIC) Lifted to Buy at HC Wainwright

March 26, 2023 | americanbankingnews.com

HC Wainwright Comments on ORIC Pharmaceuticals, Inc.'s Q1 2023 Earnings (NASDAQ:ORIC)

March 23, 2023 | markets.businessinsider.com

4 Analysts Have This to Say About ORIC Pharmaceuticals

March 23, 2023 | americanbankingnews.com

ORIC Pharmaceuticals (NASDAQ:ORIC) Price Target Cut to $15.00 by Analysts at JPMorgan Chase & Co.

March 22, 2023 | americanbankingnews.com

Oppenheimer Analysts Boost Earnings Estimates for ORIC Pharmaceuticals, Inc. (NASDAQ:ORIC)

March 21, 2023 | americanbankingnews.com

ORIC Pharmaceuticals (NASDAQ:ORIC) Upgraded by Guggenheim to Buy

March 21, 2023 | markets.businessinsider.com

Analysts Offer Insights on Healthcare Companies: Neoleukin Therapeutics (NLTX), RAPT Therapeutics (RAPT) and Oric Pharmaceuticals (ORIC)

March 16, 2023 | msn.com

Oppenheimer Upgrades ORIC Pharmaceuticals (ORIC)

March 16, 2023 | finance.yahoo.com

ORIC Pharmaceuticals Reports Fourth Quarter and Full Year 2022 Financial Results and Operational Updates

March 16, 2023 | benzinga.com

ORIC Pharmaceuticals shares are trading higher after Oppenheimer upgraded the stock from Perform to Outperform and announced a $14 price target.

March 16, 2023 | finance.yahoo.com

6 big analyst picks: Stifel says FedEx stock is a buy | Pro Recap

March 14, 2023 | finance.yahoo.com

ORIC Pharmaceuticals Announces Multiple Presentations at the 2023 American Association for Cancer Research (AACR) Annual Meeting

See More Headlines

ORIC Price History

30 days | 90 days | 365 days | Advanced Chart

ORIC Company Calendar

Last Earnings: 3/16/2023
Today: 6/01/2023
Next Earnings (Estimated): 8/10/2023
Fiscal Year End: 12/31/2023

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Industry: Pharmaceutical preparations
Sub-Industry: N/A
Sector: Medical
Current Symbol: NASDAQ:ORIC
CUSIP: N/A
CIK: 1796280
Web: www.oricpharma.com
Phone: 650-388-5600
Fax: N/A
Employees: 78
Year Founded: N/A

Price Target and Rating

Average Stock Price Forecast: $13.20
High Stock Price Forecast: $15.00
Low Stock Price Forecast: $8.00
Forecasted Upside/Downside: +161.9%
Consensus Rating: Buy
Rating Score (0-4): 3.00
Research Coverage: 5 Analysts

Profitability

EPS (Most Recent Fiscal Year): ($2.19)
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: $-89,120,000.00
Net Margins: N/A
Pretax Margin: N/A
Return on Equity: -41.01%
Return on Assets: -37.02%

Debt

Debt-to-Equity Ratio: N/A
Current Ratio: 12.99
Quick Ratio: 12.99

Sales & Book Value

Annual Sales: N/A
Price / Sales: N/A
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: $4.50 per share
Price / Book: 1.12

Miscellaneous

Outstanding Shares: 45,090,000
Free Float: 42,685,000
Market Cap: $227.25 million
Optionable: Not Optionable
Beta: 0.49

Key Executives

Dr. Richard A. Heyman Ph.D. (Age 65)
Co-Founder, Independent Chairman & Member of Scientific Advisory Board
Comp: $89.92k

Dr. Jacob M. Chacko M.B.A. (Age 43)
M.D., Pres, CEO & Director
Comp: $883.68k

Mr. Dominic G. Piscitelli CPA (Age 47)
CPA, M.B.A., Chief Financial Officer
Comp: $610.02k

Dr. Pratik S. Multani M.D. (Age 55)
M.S., Chief Medical Officer
Comp: $669.76k

Dr. Charles L. Sawyers B.A. (Age 63)
BA, M.D., Ph.D., Co-Founder & Member of Scientific Advisory Board

Dr. Scott W. Lowe Ph.D.
Co-Founder & Member of Scientific Advisory Board

Dr. Lori Sickels Friedman Ph.D. (Age 58)
Chief Scientific Officer

Dr. Christian V. Kuhlen Esq. (Age 49)
J.D., M.D., Gen. Counsel

Mr. Daniel Iazzetti
VP & Head of People

Dr. Edna Chow Maneval (Age 62)
Sr. VP of Clinical Devel.

Key Competitors

View All Competitors

Insiders & Institutions

View All Insider Transactions
View All Institutional Transactions

ORIC Stock - Frequently Asked Questions

Should I buy or sell ORIC Pharmaceuticals stock right now?: 5 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for ORIC Pharmaceuticals in the last year. There are currently 5 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" ORIC shares.
View ORIC analyst ratings or view top-rated stocks.
What is ORIC Pharmaceuticals' stock price forecast for 2023?: 5 Wall Street research analysts have issued 12-month price targets for ORIC Pharmaceuticals' stock. Their ORIC share price forecasts range from $8.00 to $15.00. On average, they predict the company's share price to reach $13.20 in the next twelve months. This suggests a possible upside of 161.9% from the stock's current price.
View analysts price targets for ORIC or view top-rated stocks among Wall Street analysts.
How have ORIC shares performed in 2023?: ORIC Pharmaceuticals' stock was trading at $5.89 at the beginning of the year. Since then, ORIC stock has decreased by 14.4% and is now trading at $5.04.
View the best growth stocks for 2023 here.
When is ORIC Pharmaceuticals' next earnings date?: The company is scheduled to release its next quarterly earnings announcement on Thursday, August 10th 2023.
View our ORIC earnings forecast.
How were ORIC Pharmaceuticals' earnings last quarter?: ORIC Pharmaceuticals, Inc. (NASDAQ:ORIC) announced its quarterly earnings results on Thursday, March, 16th. The company reported ($0.52) EPS for the quarter, topping the consensus estimate of ($0.56) by $0.04.
What other stocks do shareholders of ORIC Pharmaceuticals own?: Based on aggregate information from My MarketBeat watchlists, some companies that other ORIC Pharmaceuticals investors own include Pfizer (PFE), Intel (INTC), CrowdStrike (CRWD), Valero Energy (VLO), Hello Group (MOMO), ONEOK (OKE), DocuSign (DOCU), Vaxart (VXRT), Delta Air Lines (DAL) and Datadog (DDOG).

When did ORIC Pharmaceuticals IPO?: (ORIC) raised $75 million in an initial public offering (IPO) on Friday, April 24th 2020. The company issued 5,000,000 shares at a price of $14.00-$16.00 per share. J.P. Morgan, Citigroup, Jefferies and Guggenheim Securities served as the underwriters for the IPO.
What is ORIC Pharmaceuticals' stock symbol?: ORIC Pharmaceuticals trades on the NASDAQ under the ticker symbol "ORIC."
Who are ORIC Pharmaceuticals' major shareholders?: ORIC Pharmaceuticals' stock is owned by a variety of institutional and retail investors. Top institutional investors include FMR LLC (8.89%), Prosight Management LP (3.43%), BlackRock Inc. (1.53%), Renaissance Technologies LLC (0.76%), Geode Capital Management LLC (0.68%) and ArrowMark Colorado Holdings LLC (0.57%). Insiders that own company stock include Carl L Gordon, Dominic Piscitelli, Jacob Chacko, Orbimed Advisors Llc, Pratik S Multani, Richard A Heyman, Richard A Heyman and Richard H Scheller.
View institutional ownership trends.
How do I buy shares of ORIC Pharmaceuticals?: Shares of ORIC stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.
What is ORIC Pharmaceuticals' stock price today?: One share of ORIC stock can currently be purchased for approximately $5.04.
How much money does ORIC Pharmaceuticals make?: ORIC Pharmaceuticals (NASDAQ:ORIC) has a market capitalization of $227.25 million. The company earns $-89,120,000.00 in net income (profit) each year or ($2.19) on an earnings per share basis.
How can I contact ORIC Pharmaceuticals?: ORIC Pharmaceuticals' mailing address is 240 E. GRAND AVE. 2ND FLOOR, SOUTH SAN FRANCISCO CA, 94080. The official website for the company is www.oricpharma.com. The company can be reached via phone at 650-388-5600 or via email at investors@oricpharma.com.

This page (NASDAQ:ORIC) was last updated on 6/1/2023 by MarketBeat.com Staff

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial